Organon & Co. Operating Lease Liability
Organon & Co. (OGN) had Operating Lease Liability of $156.00 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-02-24
- 2025-12-31: Operating Lease, Liability $156.00M.
- 2024-12-31: Operating Lease, Liability $156.00M.
- 2023-12-31: Operating Lease, Liability $171.00M.
- 2022-12-31: Operating Lease, Liability $199.00M.
| Period end | Operating Lease, Liability |
|---|---|
| 2025-12-31 | $156.00M 10-K · filed 2026-02-24 |
| 2024-12-31 | $156.00M 10-K · filed 2026-02-24 |
| 2023-12-31 | $171.00M 10-K/A · filed 2025-11-10 |
| 2022-12-31 | $199.00M 10-K · filed 2024-02-26 |
| 2021-12-31 | $230.00M 10-K · filed 2023-02-27 |
| 2021-09-30 | $288.00M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $293.00M 10-Q · filed 2021-08-16 |
| 2020-12-31 | $31.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |